0OIR.LSE ALK-Abello B

Healthcare Commercial Services & Supplies London Exchange
- DKK
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
1.07%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is 0OIR.LSE undervalued?

Graham number

The Graham number of ALK-Abello B cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ALK-Abello B fundamental analysis

No fundamental analysis for ALK-Abello B yet.

ALK-Abello B stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ALK-Abello B

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ra…

Full company profile